Financial Ratios

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE14069.55-198.85 (-1.39 %)
PREV CLOSE ( ) 14268.40
OPEN PRICE ( ) 14259.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1607
TODAY'S LOW / HIGH ( )14050.00 14401.35
52 WK LOW / HIGH ( )10060 19748.4
NSE14087.00-175 (-1.23 %)
PREV CLOSE( ) 14262.00
OPEN PRICE ( ) 14270.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 14087.00 (2)
VOLUME 31110
TODAY'S LOW / HIGH( ) 14037.00 14400.00
52 WK LOW / HIGH ( )10190.7 19747
Select year
ParticularsMar2025Mar2024Mar2023Mar2022Mar2021
Operational & Financial Ratios
   Earnings Per Share (Rs)202.20233.51127.1449.5262.58
   CEPS(Rs)253.29280.05168.2887.7493.51
   DPS(Rs)12.0014.0010.005.005.00
   Book NAV/Share(Rs)1182.30994.26769.65650.56608.71
   Tax Rate(%)24.8925.2424.2122.2723.50
Margin Ratios
   Core EBITDA Margin(%)21.8229.6422.7814.9515.63
   EBIT Margin(%)23.9526.6119.1610.0113.11
   Pre Tax Margin(%)23.3925.7118.078.5911.20
   PAT Margin (%)17.5719.2213.696.688.57
   Cash Profit Margin (%)22.0023.0518.1211.8412.81
Performance Ratios
   ROA(%)12.9417.5711.024.706.29
   ROE(%)18.5826.4817.907.8610.81
   ROCE(%)23.4933.6220.999.4412.83
   Asset Turnover(x)0.740.910.800.700.73
   Sales/Fixed Asset(x)1.281.541.281.091.22
   Working Capital/Sales(x)2.223.213.794.505.35
Efficiency Ratios
   Fixed Capital/Sales(x)0.780.650.780.910.82
   Receivable days85.1786.1091.3386.7479.40
   Inventory Days90.9773.7383.4198.4091.00
   Payable days142.69119.04114.73120.79115.20
Valuation Parameters
   PER(x)59.7326.9014.1520.7333.36
   PCE(x)47.6822.4310.6911.7022.33
   Price/Book(x)10.216.322.341.583.43
   Yield(%)0.100.220.560.490.24
   EV/Net Sales(x)10.415.151.991.613.02
   EV/Core EBITDA(x)44.8516.928.4410.6017.42
   EV/EBIT(x)43.4719.3510.3916.0623.04
   EV/CE(x)9.305.912.141.432.14
   M Cap / Sales10.495.171.941.382.86
Growth Ratio
   Net Sales Growth(%)-5.2430.8425.251.5122.84
   Core EBITDA Growth(%)-27.7568.8294.81-11.2454.29
   EBIT Growth(%)-14.7381.69139.70-22.4965.88
   PAT Growth(%)-13.4183.67156.75-20.87405.63
   EPS Growth(%)-13.4183.67156.75-20.87405.63
Financial Stability Ratios
   Total Debt/Equity(x)0.090.060.120.280.22
   Current Ratio(x)2.412.121.711.571.47
   Quick Ratio(x)1.591.311.080.850.81
   Interest Cover(x)42.6329.6317.477.066.86
   Total Debt/Mcap(x)0.010.010.050.180.06

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.